CN105193751A - Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials - Google Patents
Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials Download PDFInfo
- Publication number
- CN105193751A CN105193751A CN201510664562.0A CN201510664562A CN105193751A CN 105193751 A CN105193751 A CN 105193751A CN 201510664562 A CN201510664562 A CN 201510664562A CN 105193751 A CN105193751 A CN 105193751A
- Authority
- CN
- China
- Prior art keywords
- capsule
- insulin
- microsphere
- nanoparticle
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 132
- 239000002775 capsule Substances 0.000 title claims abstract description 76
- 102000004877 Insulin Human genes 0.000 title claims abstract description 66
- 108090001061 Insulin Proteins 0.000 title claims abstract description 66
- 229940125396 insulin Drugs 0.000 title claims abstract description 66
- 239000004005 microsphere Substances 0.000 title claims abstract description 38
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000002994 raw material Substances 0.000 title claims abstract description 7
- 239000006190 sub-lingual tablet Substances 0.000 title abstract 5
- 229940098466 sublingual tablet Drugs 0.000 title abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 239000002502 liposome Substances 0.000 claims description 37
- 239000007937 lozenge Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 15
- 239000008176 lyophilized powder Substances 0.000 claims description 13
- 210000004877 mucosa Anatomy 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 229940125395 oral insulin Drugs 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 229940124532 absorption promoter Drugs 0.000 abstract description 2
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract 2
- 210000003097 mucus Anatomy 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a sublingual tablet formula and a method for preparing the sublingual tablet by using an insulin lipidosome, an insulin microsphere (capsule), and an insulin nanoparticle (capsule) as raw materials. The method is ingenious in conception; various oral sticking agents, oral mucus membrane absorption promoters, oral enzyme inhibitors and the like are scientifically selected and mixed, so that the insulin lipidosome, the insulin microsphere (capsule) and the insulin nanoparticle (capsule) can fast penetrate the oral mucus membrane to enter blood. Through the adoption of the method, a difficult problem that effects of an oral insulin can be reduced by enzymolysis of intestines and stomach enzymes and an first-pass effect of the liver is broken over; the sublingual tablet is safe, effective, controlled in slow release, stable in stability, and excellent in blood sugar reducing effect, and can completely replace an injection; a world-class difficult problem which troubles the medical field for many years can be fundamentally solved, and great convenience is brought to a patient with diabetes.
Description
Technical field
What the present invention relates to a kind of I of being used for the treatment of type and type ii diabetes prepares formula and the method for oral sublingual lozenge with insulin liposome, microsphere (capsule), nanoparticle (capsule) for raw material.Belong to protein and peptide class field of biological pharmacy.
Background technology
Oral insulin is a world-class difficult problem.Recent decades, global scientist finds the path replacing insulin injection treatment to rack brain meter, not yet has product to come out so far.The problem of core is: because insulin is protein and peptide class medicine, and molecular weight is large, fat-soluble difference and not easily through biomembrane; Oral administration can by the first pass effect of the proteolytic enzyme enzymolysis in intestines and stomach and liver and loss of activity.Many scientists are for solving the problem, and research sublingual administration directly enters blood to make it through sublingual mucosa.But due to complex process, relative bioavailability is low, poor controllability, penetration enhancer is large to the destructiveness of sublingual mucosa in addition, and safety is difficult to be guaranteed.Therefore, a kind of simple for production, the Gospel that the diabeticss that safety, curative effect are reliable, slow release is controlled, the oral insulin of good stability is all insulin injections are yearned day and night.
Summary of the invention
The technical problem to be solved in the present invention is: provide a kind of particle diameter little, be evenly distributed, envelop rate is high, have short mucosal absorption, the formula of the insulin sublingual lozenge that suppresses enzymolysis, slow release controlled and technology of preparing.It can without the proteolytic enzyme enzymolysis of intestines and stomach, under the help of mucosal absorption promoter, from Sublingual by the rapid absorption of mucosa directly controlled the entering blood and play a role of safe and effective, slow release.This prescription is skillfully constructed, technology of preparing mature and reliable, better stability of preparation, and treatment effect therapeutic effect is remarkable, is convenient to suitability for industrialized production.And low production cost, there is the powerful market competitiveness.
The formula preparing sublingual lozenge that a kind of insulin liposome, microsphere (capsule), nanoparticle (capsule) are raw material and method:
1. insulin is made liquid or the lyophilized powder of liposome or microsphere (capsule) or nanoparticle (capsule) by various materials and process.Insulin can be six aggressiveness, dimer also can be monomer.
2. the formula preparing sublingual lozenge is:
(1) liquid of insulin liposome or microsphere (capsule) or nanoparticle (capsule) or lyophilized powder 1000-3500U;
(2) cyclodextrin 500-2000mg;
(3) mannitol 200-1200mg;
(4) Polyethylene Glycol 500-1500mg;
(5) menthol 200-1200mg;
(6) alkyl polyglucoside 200-1000mg.
3. the method preparing sublingual lozenge is:
Cyclodextrin is scattered in water; Add mannitol, Macrogol 3000-20000, menthol, propylene glycol, alkyl polyglucoside again; After abundant stirring or become liquid condition, or lyophilization becomes powder.Then, slowly add insulin liposome or microsphere (capsule) or nanoparticle (capsule) liquid, or after porphyrize, add insulin liposome or microsphere (capsule) or nanoparticle (capsule) lyophilized powder, after stirring, or oven dry (temperature controls within 30 DEG C) of granulating of sieving, or regulate dry powder water content, tabletted.
Specific embodiment:
4. insulin liposome or microsphere (capsule) or nanometer (capsule) sublingual lozenge prepare formula:
(1) insulin liposome or microsphere (capsule) or nanoparticle (capsule) liquid or lyophilized powder 504U (wherein, lyophilized powder weight is 100mg, every mg insulin-containing 0.35mg)
(2) beta-schardinger dextrin-(20%) 1000mg
(3) polyethylene glycol 6000 (20%) 1000m
(4) mannitol (20%) 1000mg
(5) menthol (20%) 1000mg
(6) alkyl polyglucoside (APG0810) (18%) 900mg
The liquid of the insulin liposome in above-mentioned formula or microsphere (capsule) or nanoparticle (capsule) or lyophilized powder, or six aggressiveness, dimer and monomer; Calculate by the heavy 100mg of every sheet insulin-containing 10U/mg sheet, produce 50.Also or regulate insulin content, the heavy and output also changeable of sheet, the controlled release so that molding is eased up.
5. insulin liposome or microsphere (capsule) or nanoparticle (capsule) sublingual lozenge preparation method: by beta-schardinger dextrin-1000mg, be scattered in 12ml water; Add mannitol 1000mg, polyethylene glycol 6000 1000mg, menthol 1000mg, alkyl polyglucoside 900mg again; After abundant stirring or become liquid condition or lyophilization to become powder.Then, slowly add insulin liposome or microsphere (capsule) or nanoparticle (capsule) liquid, or add insulin liposome or microsphere (capsule) or nanoparticle (capsule) lyophilized powder, after stirring, or oven dry (temperature controls within 30 DEG C) of granulating of sieving, or regulate dry powder water content, tabletted.
The caking property of the existing tabletting of material of insulin sublingual lozenge, also has mucosal absorption to promote and suppresses the multiplicity of enzymolysis, and they promote that insulin absorbs through sublingual mucosa by the permeability of change film.They can reduce the order of the lipid molecular side direction interchain of sublingual mucosa, increase the mobility of film fat; Can the structure phase of change memebrane protein in various degree, increase the motion of memebrane protein molecule; Their relative bioavailability of effective raising.Their compound action effectively facilitates the absorption of the sublingual mucosa of insulin, and can not cause damage to sublingual mucosa.
Insulin liposome is the first-selection of islets of langerhans sublingual lozenge.Its preparation requires: particle diameter is not more than 200nm, and even particle size distribution degree is not higher than 0.20, and envelop rate is not less than 90%, and biological activity is higher than 90%.After tested, better penetrating effect can be reached.
Insulin liposome, microsphere (capsule), nanoparticle (capsule) have the preparation technology of multiple maturation, and they can make sublingual lozenge by above prescription.Above prescription can all adopt, and also can choose several combinationally using.
Insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge, also can be mixed together preparation with other material.Other material can be to other useful western medicine composition for the treatment of diabetes and Effective Component of Chinese Medicine.
Insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge, also can make hypoglossis mucous membrane, buccal paster and mucosa, nasal membrane and drop pill etc.
Insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge are common to the various types of diabetes for the treatment of.
Insulin units contained in insulin liposome, microsphere (capsule), nanoparticle (capsule) or the specification size of sublingual lozenge should be applicable to demand and the taking convenience of patient, can appraise and decide with supervision and medical department.
Claims (1)
1. prepare formula and the method for oral sublingual lozenge with insulin liposome, microsphere (capsule), nanoparticle (capsule) for raw material, it is characterized in that following steps:
1. insulin liposome, microsphere (capsule), nanoparticle (capsule) are prepared by different process for various material, and particle diameter is little, be evenly distributed, envelop rate is high, active good liquid or lyophilized powder.Insulin raw material can be six aggressiveness, also can be dimer or monomer.
2 formula preparing sublingual lozenge are:
(1) liquid of insulin liposome or microsphere (capsule) or nanoparticle (capsule) or lyophilized powder 1000-3500U;
(2) cyclodextrin 500-2000mg;
(3) mannitol 200-1200mg;
(4) Polyethylene Glycol 500-1500mg;
(5) menthol 200-1200mg;
(6) alkyl polyglucoside 200-1000mg
3. the method preparing sublingual lozenge is:
Cyclodextrin is scattered in water; Add mannitol, Macrogol 3000-20000, menthol, alkyl polyglucoside again; After abundant stirring or become liquid condition, or lyophilization becomes powder.Then, or slowly add insulin liposome or microsphere (capsule) or nanoparticle (capsule) liquid, or after porphyrize, add insulin liposome or microsphere (capsule) or nanoparticle (capsule) lyophilized powder, after stirring, or oven dry (temperature controls within 30 DEG C) of granulating of sieving, or regulate dry powder water content, tabletted.
Specific embodiment:
4. insulin liposome or microsphere (capsule) or nanoparticle (capsule) sublingual lozenge prepare formula:
(1) insulin liposome or microsphere (capsule) or nanoparticle (capsule) liquid or lyophilized powder 504U (wherein, lyophilized powder weight is 100mg, every mg insulin-containing 0.35mg)
(2) beta-schardinger dextrin-(20%) 1000mg
(3) polyethylene glycol 6000 (20%) 1000m
(4) mannitol (20%) 1000mg
(5) menthol (20%) 1000m
(6) alkyl polyglucoside (APG0810) (18%) 900mg
5. insulin liposome or microsphere (capsule) or nanoparticle (capsule) sublingual lozenge preparation method:
By beta-schardinger dextrin-1000mg, be scattered in 12ml water; Add mannitol 1000mg, polyethylene glycol 6000 1000mg, menthol 1000mg, alkyl polyglucoside 900mg again; After abundant stirring or become liquid condition or lyophilization to become powder.Then, or slowly add insulin liposome or microsphere (capsule) or nanoparticle (capsule) liquid, or add insulin liposome or microsphere (capsule) or nanoparticle (capsule) lyophilized powder, after stirring, or oven dry (temperature controls within 30 DEG C) of granulating of sieving, or regulate dry powder water content, tabletted.
6. the insulin liposome in above-mentioned formula or microsphere (capsule) or nanoparticle (capsule) or six aggressiveness, dimer and monomer; Calculate by the heavy 100mg of every sheet insulin-containing 10U/mg sheet, 50 can be produced.Also or regulate insulin content, the heavy also changeable of sheet, the controlled release so that molding is eased up.
7. insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge, deposited the good stability of quality, taking convenience at normal temperatures.
8. insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge, also can be mixed together preparation with other material.Other material can be to other useful western medicine composition for the treatment of diabetes and Effective Component of Chinese Medicine.
9. insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge, also can make hypoglossis mucous membrane, buccal paster and mucosa, nasal membrane and drop pill etc.
10. insulin liposome, microsphere (capsule), nanoparticle (capsule) sublingual lozenge are common to the various types of diabetes for the treatment of.
The caking property of the existing tabletting of 11. insulin tabletting material, also has mucosal absorption to promote and suppresses the multiplicity of enzymolysis.Their compound action effectively facilitates the absorption of the sublingual mucosa of insulin and can not cause damage to sublingual mucosa.
12. insulin liposome are first-selections of insulin tablet agent.Its preparation requires: particle diameter is not more than 200nm, and even particle size distribution degree is not higher than 0.20, and envelop rate is not less than 90%, and biological activity is higher than 90%.After tested, better penetrating effect can be reached.
13. insulin liposome, microsphere (capsule), nanoparticle (capsule) have the preparation technology of multiple maturation, and they can make sublingual lozenge by above formula.Above prescription can all adopt, and also can choose several combinationally using.
Insulin units contained in 14. insulin liposome, microsphere (capsule), nanoparticle (capsule) or the specification size of sublingual lozenge should be applicable to demand and the taking convenience of patient, can appraise and decide with supervision and medical department.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510664562.0A CN105193751A (en) | 2015-10-16 | 2015-10-16 | Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510664562.0A CN105193751A (en) | 2015-10-16 | 2015-10-16 | Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105193751A true CN105193751A (en) | 2015-12-30 |
Family
ID=54941950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510664562.0A Pending CN105193751A (en) | 2015-10-16 | 2015-10-16 | Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105193751A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107436311A (en) * | 2016-05-25 | 2017-12-05 | 正大天晴药业集团股份有限公司 | A kind of method for differentiating insulin monomer or insulin multimer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112882A2 (en) * | 2004-05-22 | 2005-12-01 | Britannia Pharmaceuticals Limited | Pharmaceutical compositions |
| US20060045869A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| WO2007036946A1 (en) * | 2005-09-28 | 2007-04-05 | Padma Venkitachalam Devarajan | Compositions for enhanced absorption of biologically active agents |
| CN1969871A (en) * | 2005-11-24 | 2007-05-30 | 北京奇源益德药物研究所 | Antivirus compound formulation, preparation process, quality control method and use thereof |
-
2015
- 2015-10-16 CN CN201510664562.0A patent/CN105193751A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112882A2 (en) * | 2004-05-22 | 2005-12-01 | Britannia Pharmaceuticals Limited | Pharmaceutical compositions |
| US20060045869A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| WO2007036946A1 (en) * | 2005-09-28 | 2007-04-05 | Padma Venkitachalam Devarajan | Compositions for enhanced absorption of biologically active agents |
| CN1969871A (en) * | 2005-11-24 | 2007-05-30 | 北京奇源益德药物研究所 | Antivirus compound formulation, preparation process, quality control method and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 雍国平: "薄荷醇β－环糊精包合物的初步研究", 《食品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107436311A (en) * | 2016-05-25 | 2017-12-05 | 正大天晴药业集团股份有限公司 | A kind of method for differentiating insulin monomer or insulin multimer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215667A1 (en) | Freeze-dried excipient and preparation method thereof | |
| CN105617362B (en) | A novel insulin-phospholipid-chitosan self-assembled microparticle carrier and its preparation | |
| CN113712895A (en) | S-ketamine medicine absorbed through oral mucosa | |
| CN102525876A (en) | Aspirin solid dispersion, as well as preparation method, pharmaceutical composition and use thereof | |
| CN104721188A (en) | Stable composition containing Alogliptin benzoate | |
| CN101773475A (en) | Preparation method of capsicine micro spheres | |
| CN105193751A (en) | Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials | |
| CN101259115B (en) | Orally-administered insulin soft capsule for treating diabetes and preparation thereof | |
| CN103830223A (en) | Applications of diosmetin in preparation of cardiovascular disease treatment medicines | |
| CN102796078A (en) | Pantoprazole compound, preparation methods and pharmaceutical preparations thereof | |
| CN102743369A (en) | N-acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN104109128B (en) | Card is rich for Buddhist nun's malate and preparation method thereof | |
| CN104983703A (en) | Prescription and preparation method of oral-administration insulin liposome, microsphere (micro-capsule) or nanoparticle (nanocapsule) sublingual lozenge | |
| CN104224728A (en) | Esomeprazole enteric-coated pellets and preparation method for same | |
| CN103271884A (en) | Lansoprazole composition and preparation method thereof | |
| CN102552358B (en) | Silymarin composition and preparation method thereof | |
| CN105412035A (en) | Colchicine sublingual tablet, preparation method and application thereof | |
| CN114796127B (en) | Electrimide sustained-release dry suspension and preparation method thereof | |
| US20100028420A1 (en) | Controlled release composition and process | |
| CN108785257B (en) | Curcumin gastric floating microsphere and preparation method thereof | |
| CN118845791B (en) | Crocetin preparation with high bioavailability and application thereof | |
| CN102552283B (en) | Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant | |
| CN101732496A (en) | Zhisuning granules and preparation method thereof | |
| CN102512371A (en) | Preparation method for forsythiaside lipidosome | |
| CN111789811B (en) | Injection solution and freeze-dried powder of honokiol for injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |